Treatment of chronic urticaria
Pro Research Analysisby 
Searched over 200M research papers
First-Line Treatment: Second-Generation Antihistamines for Chronic Urticaria
Second-generation H1 antihistamines are widely recognized as the first-line treatment for chronic urticaria due to their strong safety and efficacy profile. If symptoms persist, the dose can be increased up to four times the standard amount, although this is considered off-label use. In some cases, H2 antihistamines, leukotriene receptor antagonists, or first-generation H1 antihistamines may be added to the regimen for additional symptom control Antia2018Hon2019Beck2017+1 MORE.
Escalation of Therapy: Omalizumab and Other Biologics
For patients who do not respond to high-dose antihistamines, omalizumab, an anti-IgE monoclonal antibody, is the recommended next step. Omalizumab has significantly improved outcomes for patients with antihistamine-resistant chronic urticaria, especially chronic spontaneous urticaria (CSU). It is effective and generally safe, with evidence supporting its use in both adults and children, although data in special populations are more limited Kolkhir2019Maurer2015Wedi2021+5 MORE.
Other biologics, such as dupilumab, reslizumab, mepolizumab, and benralizumab, have shown promise in off-label use for chronic urticaria, particularly in difficult-to-treat cases. Newer anti-IgE therapies like ligelizumab and UB-221 are currently in clinical trials and may offer additional options in the future Kolkhir2019Wedi2021Wedi2022+1 MORE.
Additional and Alternative Treatments: Cyclosporine and Small Molecules
If omalizumab is ineffective, cyclosporine can be considered as an add-on therapy, often in combination with antihistamines. Other agents, such as montelukast, dapsone, and hydroxychloroquine, may be used in select cases, especially when comorbidities are present or in refractory disease. Short-term systemic corticosteroids may be used for acute exacerbations but are not recommended for long-term management due to side effects Hon2019Staubach2024Patruno2023.
Emerging treatments include Bruton’s tyrosine kinase (BTK) inhibitors (e.g., remibrutinib, rilzabrutinib, fenebrutinib), anti-cytokine therapies, and drugs targeting mast cell pathways. These are currently under investigation and may provide more targeted and personalized treatment options in the future Kolkhir2019Wedi2022Zuberbier2024.
Special Populations and Comorbidities in Chronic Urticaria Treatment
Treatment strategies for chronic urticaria in older adults and those with comorbidities generally follow the same stepwise approach as in the general population. However, careful drug selection is necessary due to potential interactions and the presence of other health conditions. Real-life data suggest that combining different treatment modalities is feasible and generally safe in patients with comorbidities Staubach2024Patruno2023.
Personalized and Future Approaches in Chronic Urticaria Management
There is a growing recognition that chronic urticaria is a heterogeneous disease with varying underlying mechanisms. Personalized, endotype-based approaches are emerging, focusing on identifying specific drivers such as autoantibodies. Novel therapies targeting different pathways, including mast cell depletion and cytokine inhibition, are being developed to address unmet needs and improve disease outcomes Kolkhir2019Wedi2022Zuberbier2024.
Conclusion
The treatment of chronic urticaria typically begins with second-generation antihistamines, escalating to higher doses if needed. Omalizumab is the preferred next step for antihistamine-resistant cases, with cyclosporine and other agents reserved for refractory disease. New biologics and small molecules are expanding the therapeutic landscape, and personalized approaches are on the horizon, promising better outcomes for patients with this challenging condition Kolkhir2019Maurer2015Wedi2021+7 MORE.
Sources and full results
Most relevant research papers on this topic
New treatments for chronic urticaria.
New treatments for chronic urticaria, including off-label use of existing drugs and novel therapies in clinical trials, show promise in improving patient outcomes.
DOI